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Abstract
Metabolomics is a systems biology tool providing small molecule signatures of disease etiology. In order to
estimate the biologic variability of the human serum metabolome, this study calculated intraclass correlation
coefficients (ICCs) for 178 stably-detected metabolites measured by untargeted chromatography/mass spec-
trometry. We studied a subsample of 60 participants (57% males, 70% Caucasians, aged 73.77 – 5.3 years) in
the Atherosclerosis Risk in Communities (ARIC) Study who provided two fasting serum samples 4–6 weeks
apart. The median ICC across all metabolites was 0.60, and 82% of metabolites had at least fair variability (i.e.,
ICC > = 0.40). There was variation in the medium-term variability among metabolites, with those in the
pathways of amino acid and lipid metabolism showing relatively high ICCs, and those in the carbohydrate
pathway showing relatively low ICCs. The results of this study provide a valuable resource for future study
design and outcome interpretation of mass spectrometry-based metabolomic studies in epidemiology.
Introduction
Metabolomics is an emerging approach to quantitatelarge numbers of low molecular weight molecules in a
biological sample (Lewis et al., 2008), and it allows for
global characterization of metabolic networks in an un-
targeted manner (Wang et al., 2011). Of the current meta-
bolomic studies, most have used a single measure of
metabolites for data analysis (Cheng et al., 2012; Suhre et al.,
2011; Wang et al., 2011), with the assumption that individual
metabolomic measurements are consistent at least over a
medium-term period. However, the metabolome is dynamic
and sensitive to external stimuli. There may be consider-
able day-to-day variations that are separate from technical
laboratory phenomena or measurement error. Thus, a single
measure of a metabolomic profile may have minimal relation
to health beyond its physiologic effects over a medium-term
period (e.g., one month). Low medium-term variability may
also lead to a situation where a metabolomic profile related to
disease may be missed (i.e., a false negative finding).
There are little data concerning medium-term, or week-to-
week, biologic variability associated with metabolomic bio-
markers (Evans et al., 2003; Floegel et al., 2011), although a
number of population studies have collected and preserved a
multitude of samples appropriate for untargeted metabolomic
measurements (Cheng et al., 2012; Sreekumar et al., 2009;
Suhre et al., 2010; 2011). The present report describes the
intraclass correlation coefficients (ICCs) (Fleiss, 1986) and
the coefficients of variation for the stably detected metabo-
lites from a convenience subsample of 60 participants in the
Atherosclerosis Risk in Communities (ARIC) Study (Wa-
genknecht et al., 2009). The study reported here investigated
the biological variability of the serum metabolome measured
by an untargeted mass spectrometry based protocol over a
period of 4–6 weeks apart.
Materials and Methods
Study population and data collection
The ARIC Study is an observational biracial cohort study
comprising 15,792 adults aged 45–64 years at baseline from
four U.S. communities: Forsyth County, NC; Jackson, MS;
suburban Minneapolis, MN; and Washington County, MD
(Investigators, 1989). As an ancillary study, the ARIC
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Carotid MRI Study consisted of 2066 ARIC participants and
was aimed to identify novel cellular, metabolic, and genomic
correlates of atherosclerotic plaque in the carotid arterial
wall. In order to quantify the variation in flow cytometry
measurements, each field center recruited 15 volunteers, and
they repeated the entire clinic visit at 4–6 weeks of their
original visit in 2005–2006 (Catellier et al., 2008). These 60
participants formed the population of current medium-term
biologic variability study. Blood samples were collected un-
der standardized conditions (investigators, 1987), and the
participants were assigned alternate phantom IDs for data
collection to ensure blinding of sample handling and labo-
ratory measurements. The average age of the participants was
73.77 – 5.3 years, and 57% of the participants were male.
African Americans made up 30% of the sample, while Cau-
casians made up the remainder (Table 1). This project
was approved by the institutional review boards at each site,
and written informed consents were provided by all study
participants.
Assessment of metabolites
Metabolite profiling was completed in June 2010 using
serum samples which had been stored at -80C since collec-
tion in 2004–2005. Metabolite levels in the serum were de-
tected and quantified by Metabolon (Durham, USA). An
untargeted, gas chromatography-mass spectrometry and liq-
uid chromatography-mass spectrometry based metabolomic
quantification protocol was used in detecting and analyzing
serum samples (60 pairs of samples for this variability study).
This approach identifies and quantifies named compounds
whose chemical identity is known, as well as additional un-
named compounds that do not currently have a chemical
standard, and these unnamed compounds were tagged begin-
ning with ‘‘X’’ and followed by numbers, such as ‘‘X-12345’’.
The samples were prepared according to the manufacturer’s
protocol (Evans et al., 2009; Ohta et al., 2009) and the assay
procedures have been described previously (Zheng et al.,
2013a). Briefly, the analytical platform used here incorporated
two separate ultrahigh performance liquid chromatography/
tandem mass spectrometry (UHPLC/MS/MS2) injections; one
injection was optimized for basic species, and the other was
optimized for acidic species. The resulting MS/MS2 data were
searched against an in-house generated authentic standard li-
brary that included retention time, molecular weight (m/z),
preferred adducts, and in-source fragments, as well as their
associated MS/MS spectra for all molecules in the library. The
instrument variability in our study was 4%, which was deter-
mined by the median relative standard deviation (%RSD) of
the injection standards, and the overall process variability was
10% by calculation %RSD of all endogenous metabolites
present in 100% of the technical replicate samples. Samples
were run over four instrument run days (i.e., 30 samples per
day). The day groups were selected serially from the shipment
box order, and each metabolite was corrected in run-day
blocks by registering the medians to equal one and normaliz-
ing each data point proportionately.
Statistical analysis
Metabolites meeting the following criteria were included
in this analysis: 1) at least 12 pairs of measureable values
across the 60 paired samples; 2) at least moderate blind du-
plicate repeatability (repeatability coefficient > 0.6) calcu-
lated from 70 duplicate samples from ARIC participants at
the baseline examination (Supplementary Data Text; sup-
plementary material is available online at www.liebertonline
.com/omi). Metabolites with low blind duplicate repeatabil-
ity indicated relatively high measurement variance or insta-
bility during sample processing were excluded in order to
focus on the components of biologic variances among those
metabolites that are stably-detected. There were 178 metab-
olites, including 106 named and 72 unnamed metabolites,
meeting both inclusion criteria. Medium-term variabilities
information for all detected metabolites, regardless of their
blind duplicate repeatability, is shown in Supplementary
Data Table S1.
To assess the medium-term variability of the serum me-
tabolites, the ICCs and 95% confidence intervals were cal-
culated using a repeated-measures mixed ANOVA model
(Weir, 2005), with metabolomic platform measurement
treated as a fixed effect and participants considered as a




2 is the between-individual variance and rw
2 is the
within-individual variance over time. SAS procedure PROC
GLM was used to partition the total variability into compo-
nents due to between participant and within participant
sources. The ICCs were categorized as: >0.75 excellent
variability, 0.40–0.75 fair to good variability, and <0.40 poor
variability (Fleiss, 1986). An ICC is a relative measure of
variability, and it has been successfully applied in previous
analyte studies (Bijari et al., 2011; Ma et al., 1995). The
coefficients of variation, calculated by standard deviation/
mean, were also presented as a dispersion measurement of
the metabolite distribution for both the between- and within-
individual components.
The level of a metabolite within a sample may be below the
detection limit of the technology. For this medium-term
variability study, each metabolite was analyzed in two ways:
without and with imputation. Without imputation, only pairs
with measureable values in both samples were included in the
analysis and the ICC is labeled as ICC_noimp. For the im-
putation, values missing/below the detected limits (m/bdl)
were assigned the lowest detected value for that metabolite in
all samples and the ICC is labeled as ICC_imp. To explore
the influence of outliers on the variability estimates, a third
ICC (i.e., ICC_imp + no_outlier) was calculated for those
metabolites with one or more outlier pairs. An outlier pair
was defined if the difference between the paired measures is







Age (years) 73.77 – 5.3 74.21 – 5.0 73.19 – 5.7
Caucasians (%) 42 (70.0) 25 (73.5) 17 (65.4)
Centers (%)
Forsyth County 7 (11.7) 5 (14.7) 2 (7.7)
Jackson 18 (30.0) 9 (26.5) 9 (34.6)
Minneapolis 15 (25.0) 8 (23.5) 7 (26.9)
Washington County 20 (33.3) 12 (35.3) 8 (30.8)
*statistics: mean – standard error for continuous variables and n
(%) for categorical variables.
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more than 3 standard deviations from the mean of the dif-
ference between paired measures among all paired observa-
tions for that metabolite.
All statistical analyses were performed in SAS version 9.2
(SAS Institute, Cary, NC).
Results
Among the 106 named metabolites, the majority were in
the pathways of lipid (N = 41) and amino acid (N = 31) me-
tabolism. The median ICC_noimp and ICC_imp for all ana-
lyzed metabolites were 0.60 and 0.63, respectively; for all
named metabolites they were 0.57 and 0.60, respectively; for
all unnamed metabolites they were 0.66 and 0.67, respec-
tively. Based on the ICC_noimp, 51 (29%) metabolites had
excellent variability, 94 (53%) had fair to good variability,
and 33 (19%) had poor variability. Overall, 82% of meta-
bolites had at least fair variability. For the ICC_imp, the
distribution of variability groups was very similar (31%,
53%, and 16%, respectively). The distribution of variability
groups across annotated pathways is shown in Figure 1. In
general, the metabolites in amino acid and lipid pathways had
higher variability than the metabolites in other pathways.
The coefficients of variance and ICCs (ICC_noimp and
ICC_imp) of metabolites in the amino acid and lipid path-
ways are shown in Table 2 and Table 3, respectively. Among
metabolites in the amino acid pathway, the medium-term
variability was lowest for 3-methylhistidine (ICC_noimp:
0.07 and ICC_imp: 0.15) and highest for indoleacetate (both
ICC_noimp and ICC_imp: 0.90), with a median ICC (both
ICC_noimp and ICC_imp) of 0.64. Among metabolites in the
lipid pathway, variability was lowest for hyodeoxycholate
(ICC_noimp: 0.22 and ICC_imp: 0.34) and highest for
pregnen-diol disulfate (both ICC_noimp and ICC_imp:
0.99), with a median ICC_noimp of 0.65 and a median IC-
C_imp of 0.60. Table 4 shows the coefficients of variance and
ICCs of metabolites in the remaining pathways (i.e., peptide,
xenobiotics, nucleotide, carbohydrate, cofactors and vita-
mins, and energy).
There were 136 metabolites that had at least one outlier
pair of measures (8 had three pairs, 40 had two pairs, and the
rest had one pair). The median difference between ICC_imp
and ICC_imp + no_outlier was 0.06, with a range of -0.23
(theophylline and X - 07765_201) to 0.77 (pyridoxate) (Fig.
2). The difference between ICC_imp and ICC_imp + no_
outlier was largest for the metabolite pyridoxate (differ-
ence = 0.77), which had only one extreme outlier pair. The
detailed information of ICC_imp + no_outlier for each me-
tabolite is shown in Supplementary Data Table 1.
Discussion
Applications of untargeted metabolomics to the study of
human disease have begun to emerge (Pirman et al., 2013;
Wetmore et al., 2010; Wikoff et al., 2007; Zheng et al., 2013a;
2013b), but few studies have investigated the medium-term
variability of the metabolomic measurements. We report that
approximately 80% of the 178 stably-detected metabolites
had at least fair medium-term variability (i.e., ICC ‡ 0.40).
Previous similar studies focused on selected metabolites of
interests (Floegel et al., 2011), were from urine samples
(Saude et al., 2007), or explored the long-term (i.e., *1 year)
variability (Sampson et al., 2013; Townsend et al., 2013). The
data presented here are to our knowledge the first medium-
term variability study of the untargeted human serum meta-
bolome, and it provides valuable information for the design
and interpretation of future metabolomic, epidemiologic, and
clinical studies.
FIG. 1. Distribution of variability
groups across pathways among 106
stably-detected named metabolites.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The variability results for several metabolites, such as
bile acids, deserve discussion as examples. Bile acids are
commonly measured as routine tests for the screening and
diagnosis of hepatobiliary disease (Steiner et al., 2011). In
this study, the median ICC_noimp and median ICC_imp of
metabolites in the bile acids pathway were 0.49 and 0.52,
respectively. In general, these metabolites had considerable
between-individual and within-individual variances among
the endogenous metabolites. This phenomenon may par-
tially result from activity of gut microflora (Swann et al.,
2011). The levels of (glycine- and taurine-) conjugated bile
acids mainly vary depending on food intake (Steiner et al.,
2011) and the conjugated bile acids in this report had gen-
erally fair variability. The levels of the unconjugated bile
acids are influenced by diurnal changes independent of
food intake (Steiner et al., 2011). In this study, even though
the samples were collected at the same time of day, the
unconjugated bile acids had generally poor variability ex-
cept for ursodeoxycholate. Previous studies relating bile
acid profiles to disease have yielded inconsistent results
(Abrams et al., 1982; Bennion and Grundy, 1977; Brufau
et al., 2010; Steiner et al., 2011), and we speculate the
relatively low over-time ICC may partially contribute to this
phenomenon.
The second example is metabolites in the sex steroids
pathway, for which the medium-term variability were gener-
ally good or excellent. Compared to a previous report in
menstruating females (Shultz et al., 2011), the results from our
males and postmenopausal females showed higher variability,
suggesting that a single sample may be enough to measure
their association with disease among an elderly population.
We further explored the difference in variability across gen-
ders (Supplementary Data Table S2). Progestagens, such as
pregn steroid monosulfate, 21-hydroxypregnenolone disulfate,
and pregnen-diol disulfate, had higher ICCs, while 5a-preg-
nan-3b,20a-diol disulfate had lower ICCs in males than that in
females. In general, androgens (andro steroid monosulfate 2,
androsterone sulfate, 5a-androstan-3b,17b-diol disulfate and
4-androsten-3b,17b-diol disulfate 2, dehydroisoandrosterone
sulfate (DHEA-S) in this study) had higher ICCs in females
than that in males.
We identified two previous studies that reported over-time
variability of human untargeted serum metabolomic mea-
surements (Sampson et al., 2013; Townsend et al., 2013). The
median unimputed ICC of 0.60 from 178 metabolites col-
lected 4–6 weeks apart reported here is higher than the me-
dian variability of 0.43 from 385 metabolites measured on
nonfasting samples from 60 Chinese females over a 1-year
period (Sampson et al., 2013). It is similar to that of 0.58 from
210 metabolites (Townsend et al., 2013) over *1.5 years
reported by Townsend et al. in a sample of 80 white Amer-
icans. The metabolites in the amino acid and lipid pathways
have higher variability than the metabolites in other pathways
(Fig. 1), and this may be expected because amino acids and
lipids are relatively endogenous and genetically regulated
compared to the metabolites in carbohydrate and xenobiotic
pathways that are more likely to be influenced by the dietary
intake and other environmental factors. This phenomenon
may partially explain the observation that prominent findings
in metabolomic biomarker discovery are often amino acids
and lipids (Menni et al., 2013; Newgard et al., 2009; Wang
et al., 2011).
There are a large number of factors that may influence the
over-time variability of metabolites, including the time be-
tween measurements, selection of the metabolites, and the
age, race, gender, life style, and overall health status of the
study sample (Chambless et al., 1992). Similar to the previ-
ous studies (Floegel et al., 2011; Sampson et al., 2013), a
limitation of the current report is the relatively small sample
size, and restricted capability to assess these potential influ-
ences on the variability of metabolites. The study has been
conducted among elderly ARIC participants in the U.S.;
special attention should be paid when we generalize results to
other populations.
There may be bias in studies of association between a
single metabolite measurement and disease when the
within-individual variance of the metabolite, including bi-
ology variance and measurement error, is large compared to
the between-individual variance (i.e., ICC <0.5) (Floegel
et al., 2011; Verghese et al., 2011). In simple linear or lo-
gistic regressions, it leads to bias toward the null hypothesis;
that is, the size of relationship between the metabolite and
the outcome under consideration is underestimated (Fuller,
1987). There are two possible ways to solve this problem
(Chambless et al., 1992). One is to decrease the measure-
ment variation by refining laboratory processes or making
FIG. 2. The distribution of difference between
ICC_imp and ICC_imp + no_outlier among 136
metabolites that had at least one outlier pair of
observations.
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multiple measurements. The second solution is to adjust the
estimate of relationships between a metabolite and disease
for the amount of within-individual variation in the inde-
pendent variable (e.g., the metabolite). For simple regres-
sions this is accomplished by replacing the ordinary
estimate b̂ord with b̂adj¼ b̂ord=ICC (Chambless et al., 1992).
Therefore, for metabolites with low ICCs as the potential
predictor variable of interest, the above equation suggests
the way to adjust for ICC in estimating the relationship
between a metabolite and disease. However, the true ICC of
a metabolite over a certain period is seldom known.
Conclusions
We report the medium-term variability for untargeted
metabolomic measurements in the human serum from 60
individuals from four U.S. communities having two fasting
samples collected 4–6 weeks apart. The median ICC was
0.60, and imputation of values below the detection limit had
little impact on this estimate, and as expected, the impact of
outliers in ICC varies among metabolites. There was varia-
tion among metabolites in this estimate with those in the
pathways of amino acid and lipid metabolism showing higher
ICCs, and those in the carbohydrate pathway showing lower
ICCs. The results of this study serve as a resource to aid future
study design and result interpretation.
Acknowledgments
The authors thank the staff and participants of the Athero-
sclerosis Risk in Communities (ARIC) Study for their important
contributions. The ARIC Study is a collaborative study sup-
ported by the National Heart, Lung, and Blood Institute, Na-
tional Institutes of Health, Contracts HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN26-
82011-00008C, HHSN268201100009C, HHSN2682011000-
10C, HHSN268201100011C, and HHSN268201100012C. The
metabolomics research was sponsored by the National Human
Genome Research Institute (3U01HG004402-02S1). YZ and
BY are supported in part by a training fellowship from the
Burroughs Wellcome Fund (Grant 1008200).
Author Disclosure Statement
The authors declare that no competing financial interests
exist.
References
Abrams JJ, Ginsberg H, and Grundy SM. (1982). Metabolism of
cholesterol and plasma triglycerides in nonketotic diabetes
mellitus. Diabetes 31, 903–910.
Bennion LJ, and Grundy SM. (1977). Effects of diabetes mel-
litus on cholesterol metabolism in man. N Engl J Med 296,
1365–1371.
Bijari PB, Antiga L, Wasserman BA, and Steinman DA. (2011).
Scan-Rescan reproducibility of carotid bifurcation geometry
from routine contrast-enhanced MR angiography. J Magn
Reson Imaging 33, 482–489.
Brufau G, Stellaard F, Prado K, et al. (2010). Improved gly-
cemic control with colesevelam treatment in patients with
type 2 diabetes is not directly associated with changes in bile
acid metabolism. Hepatology 52, 1455–1464.
Catellier DJ, Aleksic N, Folsom AR, and Boerwinkle E. (2008).
Atherosclerosis Risk in Communities (ARIC) Carotid MRI
flow cytometry study of monocyte and platelet markers: In-
traindividual variability and reliability. Clin Chem 54, 1363–
1371.
Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G,
and Shen YL. (1992). Short-term intraindividual variability in
lipoprotein measurements: The Atherosclerosis Risk in Com-
munities (ARIC) Study. Am J Epidemiol 136, 1069–1081.
Cheng S, Rhee EP, Larson MG, et al. (2012). Metabolite pro-
filing identifies pathways associated with metabolic risk in
humans. Circulation 125, 2222–2231.
Evans AM, Dehaven CD, Barrett T, Mitchell M, and Milgram
E. (2009). Integrated, nontargeted ultrahigh performance
liquid chromatography/electrospray ionization tandem mass
spectrometry platform for the identification and relative
quantification of the small-molecule complement of biologi-
cal systems. Anal Chem 81, 6656–6667.
Evans DA, Bennett DA, Wilson RS, et al. (2003). Incidence of
Alzheimer disease in a biracial urban community: Relation to
apolipoprotein E allele status. Arch Neurol 60, 185–189.
Fleiss J. (1986). The Design and Analysis of Clinical Experi-
ments. John Wiley & Sons, New York, NY.
Floegel A, Drogan D, Wang-Sattler R, et al. (2011). Reliability
of serum metabolite concentrations over a 4-month period
using a targeted metabolomic approach. PLoS One 6, e21103.
Fuller W. (1987). Measurement Error Models. John Wiley,
New York.
Investigators TA. (1987). Atherosclerosis Risk in Communities
Study. Operations manual. No. 9: Hemostasis determinations,
version 1.0. National Heart, Lung, and Blood Institute., Be-
thesda, MD.
Investigators TA. (1989). The Atherosclerosis Risk in Com-
munities (ARIC) Study: design and objectives. The ARIC
investigators. Am J Epidemiol 129, 687–702.
Lewis GD, Asnani A, and Gerszten RE. (2008). Application of
metabolomics to cardiovascular biomarker and pathway dis-
covery. J Am Coll Cardiol 52, 117–123.
Ma J, Folsom AR, Eckfeldt JH, Lewis L, and Chambless LE.
(1995). Short- and long-term repeatability of fatty acid
composition of human plasma phospholipids and cholesterol
esters. The Atherosclerosis Risk in Communities (ARIC)
Study Investigators. Am J Clin Nutr 62, 572–578.
Menni C, Fauman E, Erte I, et al. (2013). Biomarkers for type 2
diabetes and impaired fasting glucose using a nontargeted
metabolomics approach. Diabetes 62, 4270–4276.
Newgard CB, An J, Bain JR, et al. (2009). A branched-chain
amino acid-related metabolic signature that differentiates
obese and lean humans and contributes to insulin resistance.
Cell Metab 9, 311–326.
Ohta T, Masutomi N, Tsutsui N, et al., (2009). Untargeted
metabolomic profiling as an evaluative tool of fenofibrate-
induced toxicology in Fischer 344 male rats. Toxicol Pathol
37, 521–535.
Pirman DA, Efuet E, Ding XP, et al. (2013). Changes in cancer
cell metabolism revealed by direct sample analysis with
MALDI mass spectrometry. PLoS One 8, e61379.
Sampson JN, Boca SM, Shu XO, et al. (2013). Metabolomics in
epidemiology: Sources of variability in metabolite measure-
ments and implications. Cancer Epidemiol Biomarkers Prev
22, 631–640.
Saude E, Adamko D, Rowe B, Marrie T, and Sykes B. (2007).
Variation of metabolites in normal human urine. Metabo-
lomics 3, 439–451.
372 ZHENG ET AL.
Shultz SJ, Wideman L, Montgomery MM, and Levine BJ.
(2011). Some sex hormone profiles are consistent over time in
normal menstruating women: Implications for sports injury
epidemiology. Br J Sports Med 45, 735–742.
Sreekumar A, Poisson LM, Rajendiran TM, et al. (2009). Me-
tabolomic profiles delineate potential role for sarcosine in
prostate cancer progression. Nature 457, 910–914.
Steiner C, Othman A, Saely CH, et al., (2011). Bile acid me-
tabolites in serum: Intraindividual variation and associations
with coronary heart disease, metabolic syndrome and diabetes
mellitus. PLoS One 6, e25006.
Suhre K, Meisinger C, Doring A, et al., (2010). Metabolic
footprint of diabetes: A multiplatform metabolomics study in
an epidemiological setting. PLoS One 5, e13953.
Suhre K, Shin SY, Petersen AK, et al., (2011). Human meta-
bolic individuality in biomedical and pharmaceutical re-
search. Nature 477, 54–60.
Swann JR, Want EJ, Geier FM, et al., (2011). Systemic gut
microbial modulation of bile acid metabolism in host tissue
compartments. Proc Natl Acad Sci USA 108 Suppl 1, 4523–
4530.
Townsend MK, Clish CB, Kraft P, et al. (2013). Reproducibility
of metabolomic profiles among men and women in 2 large
cohort studies. Clin Chem 59, 1657–1667.
Verghese PB, Castellano JM, and Holtzman DM. (2011).
Apolipoprotein E in Alzheimer’s disease and other neuro-
logical disorders. Lancet Neurol 10, 241–252.
Wagenknecht L, Wasserman B, Chambless L, et al. (2009).
Correlates of carotid plaque presence and composition as
measured by MRI: The Atherosclerosis Risk in Communities
Study. Circ Cardiovasc Imaging 2, 314–322.
Wang TJ, Larson MG, Vasan RS, et al. (2011). Metabolite
profiles and the risk of developing diabetes. Nat Med 17,
448–453.
Weir JP. (2005). Quantifying test-retest reliability using the
intraclass correlation coefficient and the SEM. J Strength
Cond Res 19, 231–240.
Wetmore DR, Joseloff E, Pilewski J, et al. (2010). Metabolomic
profiling reveals biochemical pathways and biomarkers as-
sociated with pathogenesis in cystic fibrosis cells. J Biol
Chem 285, 30516–30522.
Wikoff WR, Gangoiti JA, Barshop BA, and Siuzdak G. (2007).
Metabolomics identifies perturbations in human disorders of
propionate metabolism. Clin Chem 53, 2169–2176.
Zheng Y, Yu B, Alexander D, et al. (2013a). Associations be-
tween metabolomic compounds and incident heart failure
among African Americans: The ARIC Study. Am J Epide-
miol 178, 534–542.
Zheng Y, Yu B, Alexander D, et al., (2013b). Metabolomics and
incident hypertension among blacks: The atherosclerosis risk
in communities study. Hypertension 62, 398–403.
Address correspondence to:
Eric Boerwinkle, PhD






ARIC¼Atherosclerosis Risk in Communities
DHEA-S¼ dehydroisoandrosterone sulfate
ICCs¼ intraclass correlation coefficients
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